Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.

Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, Enk AH, Hassel JC.

Immunotherapy. 2016 Sep;8(9):1033-44. doi: 10.2217/imt-2016-0083.

PMID:
27485076
2.

"Watching the Detectives" report of the general assembly of the EU project DETECTIVE Brussels, 24-25 November 2015.

Fernando RN, Chaudhari U, Escher SE, Hengstler JG, Hescheler J, Jennings P, Keun HC, Kleinjans JC, Kolde R, Kollipara L, Kopp-Schneider A, Limonciel A, Nemade H, Nguemo F, Peterson H, Prieto P, Rodrigues RM, Sachinidis A, Schäfer C, Sickmann A, Spitkovsky D, Stöber R, van Breda SG, van de Water B, Vivier M, Zahedi RP, Vinken M, Rogiers V.

Arch Toxicol. 2016 Jun;90(6):1529-39. doi: 10.1007/s00204-016-1719-6. Epub 2016 Apr 29.

PMID:
27129694
3.

Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).

Portier CJ, Armstrong BK, Baguley BC, Baur X, Belyaev I, Bellé R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM, Carpenter DO, Carpenter HM, López-Carrillo L, Clapp R, Cocco P, Consonni D, Comba P, Craft E, Dalvie MA, Davis D, Demers PA, De Roos AJ, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, Hauptmann M, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Rodriguez T, Röösli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PT, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DD, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou SF.

J Epidemiol Community Health. 2016 Aug;70(8):741-5. doi: 10.1136/jech-2015-207005. Epub 2016 Mar 3. No abstract available.

4.

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.

Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8.

PMID:
26855150
5.

Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):70-83. doi: 10.1007/s00259-015-3206-3. Epub 2015 Oct 28.

PMID:
26508290
6.

Cell type-specific expression and localization of cytochrome P450 isoforms in tridimensional aggregating rat brain cell cultures.

Vichi S, Sandström von Tobel J, Gemma S, Stanzel S, Kopp-Schneider A, Monnet-Tschudi F, Testai E, Zurich MG.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):176-84. doi: 10.1016/j.tiv.2015.03.005. Epub 2015 Mar 17.

PMID:
25795400
7.

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, Oehme I.

Cell Death Dis. 2015 Feb 19;6:e1657. doi: 10.1038/cddis.2015.24.

8.

Quantitative in vitro to in vivo extrapolation of tissues toxicity.

Hamon J, Renner M, Jamei M, Lukas A, Kopp-Schneider A, Bois FY.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):203-16. doi: 10.1016/j.tiv.2015.01.011. Epub 2015 Feb 9.

PMID:
25678044
9.

Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing.

Limonciel A, Moenks K, Stanzel S, Truisi GL, Parmentier C, Aschauer L, Wilmes A, Richert L, Hewitt P, Mueller SO, Lukas A, Kopp-Schneider A, Leonard MO, Jennings P.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18. doi: 10.1016/j.tiv.2014.12.011. Epub 2015 Jan 13.

PMID:
25596134
10.

Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.

Savary CC, Jiang X, Aubry M, Jossé R, Kopp-Schneider A, Hewitt P, Guillouzo A.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35. doi: 10.1016/j.tiv.2014.12.019. Epub 2015 Jan 5.

PMID:
25572481
11.

Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study.

Aschauer L, Limonciel A, Wilmes A, Stanzel S, Kopp-Schneider A, Hewitt P, Lukas A, Leonard MO, Pfaller W, Jennings P.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):106-16. doi: 10.1016/j.tiv.2014.10.005. Epub 2014 Oct 23.

PMID:
25450743
12.

Statistical strategies for averaging EC50 from multiple dose-response experiments.

Jiang X, Kopp-Schneider A.

Arch Toxicol. 2015 Nov;89(11):2119-27. doi: 10.1007/s00204-014-1350-3. Epub 2014 Oct 8.

PMID:
25294322
13.
14.

Quantitative Emphysema Distribution in Anatomic and Non-anatomic Lung Regions.

Owsijewitsch M, Ley-Zaporozhan J, Kuhnigk JM, Kopp-Schneider A, Eberhardt R, Eichinger M, Heussel CP, Kauczor HU, Ley S.

COPD. 2015 Jun;12(3):257-66. doi: 10.3109/15412555.2014.933950. Epub 2014 Sep 17.

PMID:
25230093
15.

Optimal experimental designs for dose-response studies with continuous endpoints.

Holland-Letz T, Kopp-Schneider A.

Arch Toxicol. 2015 Nov;89(11):2059-68. doi: 10.1007/s00204-014-1335-2. Epub 2014 Aug 26.

16.

Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.

Koerber SA, Slynko A, Haefner MF, Krug D, Schoneweg C, Kessel K, Kopp-Schneider A, Herfarth K, Debus J, Sterzing F.

Radiat Oncol. 2014 May 13;9:113. doi: 10.1186/1748-717X-9-113.

17.

Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.

Wielpütz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, Eichinger M, Mall MA.

Am J Respir Crit Care Med. 2014 Apr 15;189(8):956-65. doi: 10.1164/rccm.201309-1659OC.

PMID:
24564281
18.

Summarizing EC50 estimates from multiple dose-response experiments: a comparison of a meta-analysis strategy to a mixed-effects model approach.

Jiang X, Kopp-Schneider A.

Biom J. 2014 May;56(3):493-512. doi: 10.1002/bimj.201300123. Epub 2014 Jan 29.

PMID:
24478144
19.

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE.

Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13.

20.

Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):887-97. doi: 10.1007/s00259-013-2660-z. Epub 2013 Dec 19.

PMID:
24352789
Items per page

Supplemental Content

Loading ...
Write to the Help Desk